Physicians have a new option for minimally invasive TLIF, PLIF procedures

Life Spine Inc. has received U.S. Food and Drug Administration 510(k) clearance for its VersaLift Expandable Interbody System, a Micro Invasive solution designed for transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) procedures, the company announced.

The implant's defining feature is its starting height of 6mm, which Life Spine says is among the smallest available for a TLIF expandable interbody device. The low-profile design is intended to support insertion through constrained anatomy while reducing tissue disruption and nerve retraction during placement, according to the company.

VersaLift is cleared in 8mm, 10mm and 12mm widths, with up to 15 degrees of lordotic correction available. The system uses controlled in-situ expansion, which Life Spine says is designed to maintain implant length throughout deployment while supporting restoration of anatomic disc height and indirect decompression of neural elements. The company said streamlined instrumentation is intended to help surgeons maintain alignment and procedural efficiency throughout the case.

"VersaLift represents our continued focus on procedural innovation and minimally invasive spine surgery," said Rich Mueller, president and CEO of Life Spine, in a statement. "By combining a 6mm starting height with controlled in-situ expansion, VersaLift provides surgeons with a versatile expandable technology designed to address challenging anatomy while supporting procedural efficiency."

Life Spine markets VersaLift as part of its broader Micro Invasive platform, a line of products the company says is built around reducing surgical footprint without compromising the clinical goals of traditional open procedures. The 510(k) pathway clearance allows the device to be marketed in the U.S. based on substantial equivalence to a predicate device already on the market.

Expandable interbody technology continues to evolve

VersaLift's clearance reflects a broader trend in spine surgery toward smaller-profile, expandable interbody devices that allow surgeons to insert implants through narrower surgical corridors and then expand them in place to restore disc height and spinal alignment. This approach has become increasingly central to minimally invasive TLIF and PLIF techniques, which aim to limit muscle and soft-tissue disruption compared with traditional open fusion procedures.

Surgeons performing minimally invasive lumbar fusion have generally sought implants that combine a low starting profile for insertion with the ability to expand to a height and lordotic angle appropriate for the patient's anatomy, all while preserving structural integrity under load. Device makers in this space have continued to refine in-situ expansion mechanisms, instrumentation, and material science with the goal of giving surgeons more predictable control during deployment.

As lumbar degenerative disc disease and spinal stenosis remain common indications for fusion surgery, demand has grown for implant systems that can address a range of anatomical presentations without requiring multiple separate product lines. Expandable interbody platforms are designed to give surgeons intraoperative flexibility, reducing the need to plan for every possible anatomical variation before the procedure begins. Continued refinement of these systems, including smaller starting heights and more controlled expansion mechanics, is likely to remain a focus area for spine device manufacturers as minimally invasive techniques become more standard across lumbar fusion procedures.